Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology.

{"article_title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology.","author":"Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A","journal_title":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","issn":"1878-3562","isbn":"","publication_date":"2022-04-01","volume":"54","issue":"4","first_page":"428","page_count":"","accession_number":"35183439","doi":"10.1016\/j.dld.2022.01.123","publisher":"Elsevier","doctype":"Practice Guideline","subjects":"Biological Products therapeutic use; Colitis, Ulcerative drug therapy; Adalimumab therapeutic use; Adult; Humans; Infliximab therapeutic use; Ustekinumab therapeutic use","interest_area":["Gastroenterology"],"abstract":"The increased knowledge on the biological mechanisms underlying ulcerative colitis (UC) has triggered an advance in drug development, drastically changing the therapeutic landscape. Several biologics and small-molecule drugs have been regulatory approved (i.e., infliximab, adalimumab, golimumab, vedolizumab, ustekinumab and tofacitinib), and frequently pose clinical dilemmas: physicians need to know how these therapies can be used to optimize patient-important outcomes. Adhering to the \"Grading of Recommendations Assessment, Development and Evaluation\" (GRADE) methodology, this technical review systematically searched and identified the evidence, synthesized it using rigorous meta-analytic methodology, appraised its quality, and concisely presented it in a transparent way, forming the basis for developing clinical recommendations on the use of biologics and small-molecule drugs in adult patients with UC. Competing Interests: Conflict of interest Fabio Macaluso has served as an advisory board member and\/or received lecture grants from AbbVie, Biogen, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. Ambrogio Orlando has served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. Stefano Festa has served as an advisory board member for Janssen Cilag, and received consultancy fees and\/or educational grants from Takeda, SoFar, Abbvie, and Zambon. Claudio Papi has received consultancy fees and\/or educational grants from Abbvie, MSD, Takeda, Pfizer, Janssen-Cilag, Sandoz, Chiesi, Sofar, Ferring and Zambon. Daniela Pugliese has received consultancy fees from Takeda, Jannsen-Cilag, Pfizer, and MSD. Alessandro Armuzzi has received consulting and\/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda; lecture and\/or speaker bureau fees from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix, and research grants from MSD, Pfizer, Takeda. Stefanos Bonovas, Claudia Pansieri and Daniele Piovani have no conflicts of interest to declare. Copyright \u00a9 2022. Published by Elsevier Ltd.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=35183439","isPdfLink":false,"isSAML":false,"an":"35183439","number_other":"","type_pub":"","issn_electronic":"1878-3562","languages":"English","language":"eng","date_entry":"Date Created: 20220220 Date Completed: 20220505 Latest Revision: 20220505","date_update":"20240105","titleSource":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2022 Apr; Vol. 54 (4), pp. 428-439. Date of Electronic Publication: 2022 Feb 17.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-04-01","description":"The increased knowledge on the biological mechanisms underlying ulcerative colitis (UC) has triggered an advance in drug development, drastically changing the therapeutic landscape. Several biologics and small-molecule drugs have been regulatory approved (i.e., infliximab, adalimumab, golimumab, vedolizumab, ustekinumab and tofacitinib), and frequently pose clinical dilemmas: physicians need to know how these therapies can be used to optimize patient-important outcomes. Adhering to the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) methodology, this technical review systematically searched and identified the evidence, synthesized it using rigorous meta-analytic methodology, appraised its quality, and concisely presented it in a transparent way, forming the basis for developing clinical recommendations on the use of biologics and small-molecule drugs in adult patients with UC.<br \/>Competing Interests: Conflict of interest Fabio Macaluso has served as an advisory board member and\/or received lecture grants from AbbVie, Biogen, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. Ambrogio Orlando has served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. Stefano Festa has served as an advisory board member for Janssen Cilag, and received consultancy fees and\/or educational grants from Takeda, SoFar, Abbvie, and Zambon. Claudio Papi has received consultancy fees and\/or educational grants from Abbvie, MSD, Takeda, Pfizer, Janssen-Cilag, Sandoz, Chiesi, Sofar, Ferring and Zambon. Daniela Pugliese has received consultancy fees from Takeda, Jannsen-Cilag, Pfizer, and MSD. Alessandro Armuzzi has received consulting and\/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda; lecture and\/or speaker bureau fees from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix, and research grants from MSD, Pfizer, Takeda. Stefanos Bonovas, Claudia Pansieri and Daniele Piovani have no conflicts of interest to declare.<br \/> (Copyright © 2022. Published by Elsevier Ltd.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=35183439&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A"}